

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

*(Incorporated in the Cayman Islands with Limited Liability)*

**(Stock Code: 1801)**

## **PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION**

This announcement is made by Innovent Biologics, Inc. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to the proposed adoption of the new memorandum and articles of association of the Company (the “**Memorandum and Articles of Association**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to amend certain provisions of its existing Memorandum and Articles of Association by way of adoption of the new Memorandum and Articles of Association to (i) bring the existing Memorandum and Articles of Association in line with amendments made to Appendix 3 to the Listing Rules which came into effect on January 1, 2022; (ii) provide flexibility to the Company in relation to the conduct of general meetings; and (iii) make other consequential and housekeeping changes.

The proposed adoption of the new Memorandum and Articles of Association is subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting of the Company to be held on June 21, 2023 (the “**AGM**”) and if approved by the Shareholders, will become effective upon the approval by the Shareholders at the AGM. A circular containing, among others, details of the proposed adoption of the new Memorandum and Articles of Association and a notice convening the AGM will be despatched to the Shareholders as soon as practicable.

By Order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, China, May 29, 2023

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director; and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.*